- Home
- UFCS vs HUMA Comparison
UFCS vs HUMA Comparison
Compare UFCS & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- HUMA
- Stock Information
- Founded
- UFCS 1946
- HUMA 2004
- Country
- UFCS United States
- HUMA United States
- Employees
- UFCS N/A
- HUMA N/A
- Industry
- UFCS Property-Casualty Insurers
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- HUMA Health Care
- Exchange
- UFCS Nasdaq
- HUMA Nasdaq
- Market Cap
- UFCS 666.1M
- HUMA 367.6M
- IPO Year
- UFCS N/A
- HUMA N/A
- Fundamental
- Price
- UFCS $27.47
- HUMA $2.34
- Analyst Decision
- UFCS Buy
- HUMA Strong Buy
- Analyst Count
- UFCS 2
- HUMA 7
- Target Price
- UFCS $30.00
- HUMA $13.00
- AVG Volume (30 Days)
- UFCS 138.2K
- HUMA 3.4M
- Earning Date
- UFCS 08-05-2025
- HUMA 08-12-2025
- Dividend Yield
- UFCS 2.32%
- HUMA N/A
- EPS Growth
- UFCS N/A
- HUMA N/A
- EPS
- UFCS 2.54
- HUMA N/A
- Revenue
- UFCS $1,288,423,000.00
- HUMA $517,000.00
- Revenue This Year
- UFCS $11.31
- HUMA N/A
- Revenue Next Year
- UFCS $10.61
- HUMA $858.42
- P/E Ratio
- UFCS $10.84
- HUMA N/A
- Revenue Growth
- UFCS 14.59
- HUMA N/A
- 52 Week Low
- UFCS $18.04
- HUMA $1.15
- 52 Week High
- UFCS $31.70
- HUMA $9.79
- Technical
- Relative Strength Index (RSI)
- UFCS 47.26
- HUMA 54.42
- Support Level
- UFCS $26.61
- HUMA $2.28
- Resistance Level
- UFCS $28.10
- HUMA $2.57
- Average True Range (ATR)
- UFCS 0.68
- HUMA 0.19
- MACD
- UFCS -0.05
- HUMA 0.01
- Stochastic Oscillator
- UFCS 42.31
- HUMA 53.15
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.